Press Releases
Cleveland Diagnostics’ Prostate Cancer Awareness Campaign ‘A PSA on PSA’ Returns This September
READ MORE
08.27.24
Cleveland Diagnostics Adds Dara Grantham Wright to Board of Directors
READ MORE
07.23.24
Cleveland Diagnostics Completes $75M Financing to Advance its Early-detection Oncology Testing Platform
READ MORE
1.17.24
Cleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’
READ MORE
8.30.23
Cleveland Diagnostics Opens New Facility Amid Growing Demand for IsoPSA® Test
READ MORE
6.28.23
Cleveland Diagnostics Announces Agreement with Quest Diagnostics to Expand Patient Access to IsoPSA® Prostate Cancer Testing
READ MORE
2.13.23
Cleveland Diagnostics Announces the Publication of Two Major IsoPSA® Studies
READ MORE
10.31.22
Cleveland Diagnostics Announces Favorable Medicare Local Coverage Determination and Assignment of a CPT-PLA Code for IsoPSA®
READ MORE
10.13.22
Cleveland Diagnostics Announces Inclusion of IsoPSA® in National Comprehensive Cancer Network® Guidelines for Prostate Cancer Early Detection
READ MORE
5.11.22
Cleveland Diagnostics Announces Publication of Real-World Study Demonstrating the Clinical Utility of IsoPSA® for Prostate Cancer Risk Assessment
READ MORE
2.23.22
Cleveland Diagnostics Presents New Data Supporting the Clinical Validation and Clinical Utility of IsoPSA at the 2021 Annual Meeting of American Urological Association
READ MORE
9.14.21
Cleveland Diagnostics Receives College of American Pathologists (CAP) Accreditation for Its Clinical Laboratory
READ MORE
5.5.21
News
9.30.24
Cleveland Diagnostics’ PSA on PSA targets the falling screening rates for prostate cancer
READ MORE
Changing the Shape of Prostate Cancer Detection
READ MORE
9.13.24
How Prostate Cancer Screening Advancements Are Reducing Overtreatment
READ MORE
9.10.24
Cleveland Diagnostics re-ups prostate-specific antigen test push in 'A PSA on PSA'
READ MORE
8.27.24
Bridging the gap: Mitigating disparities in prostate cancer outcomes
READ MORE
7.10.24
The potential role for IsoPSA in prostate cancer risk assessment
READ MORE
6.23.24
Dr. Hafron on IsoPSA with PI-RADS for prostate biopsy decision-making
READ MORE
6.13.24
The Cost of Overtreatment: How Improved Cancer Diagnostics Can Help Preserve Key Healthcare Resources
READ MORE
5.10.24
The NASA Scientist Who Changed Cancer Diagnostics Forever
READ MORE
5.7.24
Mark Stovsky of Cleveland Diagnostics On The 5 Things Everyone Needs To Know About Cancer
READ MORE
4.16.24
Reducing The Cost Of Cancer With Improved Diagnostics
READ MORE
3.21.24
Clearer Diagnostics, Improved Chances: The Big-Picture Impacts of Improved Cancer Diagnostic Testing
READ MORE
2.14.24
The great prostate debate: innovations in prostate cancer screening
READ MORE
2.6.24
Cleveland Diagnostics receives $75M in financing
READ MORE
2.5.24
Easing a Burdened Healthcare System with Improved Cancer Diagnostics
READ MORE
1.30.24
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
READ MORE
1.30.24
Next-gen prostate cancer test maker Cleveland Diagnostics rocks to $75M fundraising
READ MORE
1.29.24
Cleveland Diagnostics Aims to Drive IsoPSA Test Into New Prostate Cancer Indications, Markets
READ MORE
1.29.24
Cleveland Diagnostics raises $75 million to expand cancer tests
READ MORE
1.17.24
Cleveland Diagnostics secures over $75 million in funding for early detection cancer tests
READ MORE
1.17.24
Advancements in Cancer Diagnostics Creating More Accurate Risk Analysis and Patient Options with Arnon Chait Cleveland Diagnostics
READ MORE
1.11.24
When it Comes to Cancer Diagnostics, Simpler May Be Better
READ MORE
11.17.23
Bob Rochelle of Cleveland Diagnostics on Life Science Success
READ MORE
11.16.23
Movember movement puts spotlight on men's health
READ MORE
11.14.23
Refocusing the Lens of Cancer Screening
READ MORE
9.19.23
'A PSA On PSA' Fights Prostate Cancer
READ MORE
9.11.23
Cleveland Diagnostics has a PSA on PSAs in prostate cancer push
READ MORE
08.31.23
Diagnostics company opens new facility to scale up production of IsoPSA test for prostate cancer
READ MORE
06.30.23
Dr. Abdallah discusses new research on IsoPSA for prostate cancer
READ MORE
02.16.23
IsoPSA Shows Notable Diagnostic Accuracy in Detecting Prostate Cancer
READ MORE
7.20.22
Eric Klein, MD from the Glickman Urological and Kidney Institute at the Cleveland Clinic speaks about the AUA 2021 Abstract - MP60-03 IsoPSA: Clinical performance of a single parameter, structure based test for high grade prostate cancer in a large, multicenter, prospective validation trial.
READ MORE
10.14.21
How New Blood Tests May Be Able to Detect Cancer Earlier and Easier
READ MORE
10.3.21
Prostate Cancer Blood Test Helps Man Receive Prompt Treatment
READ MORE
9.30.21
